(Bloomberg) -- Teva Pharmaceutical Industries Ltd. lost an appeals court bid to revive four patents on its top-selling multiple sclerosis drug Copaxone.
A trial judge was correct to invalidate the four Teva patents, the U.S. Court of Appeals for the Federal Circuit said Friday in an opinion on its electronic docket. The decision was a victory for generic-drug makers including Mylan NV and Novartis AG’s Sandoz.
To contact the reporter on this story: Susan Decker in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Jon Morgan at email@example.com
©2018 Bloomberg L.P.